GSK Market Shock: US Restrictions on Respiratory Vaccine Cause Massive Stock Drop

GSK Faces Major Market Hurdle

In a sudden development, GlaxoSmithKline (GSK) is reeling from a massive loss of almost £5 billion in market value, triggered by regulatory restrictions on its flagship respiratory vaccine.

US CDC's Crucial Directive

The US Centers for Disease Control and Prevention's advice against vaccinating individuals under 60 with respiratory syncytial virus jabs has dealt a severe blow to GSK's market prospects.

• Stock Freefall: GSK's shares plummet as investors react to the significant setback.

Overall, the restriction on the vaccine raises critical questions about GSK's future strategic moves and risk management practices in the pharmaceutical sector.